ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Yarbro To Leave As NCI Centers Chief to Head Missouri Cancer Program; Replaced By Cantril

May 30, 1975

NCI Programs: Director Challenges Scientists To Develop Molecular “Fingerprints” Of Tumors

December 4, 1998

NCI Study Tests Method For Biomarker Validation

July 24, 2009

ASCO to form commission to study tobacco problem.

January 23, 2004

FDA Approves Votrient For Renal Cell Carcinoma

October 23, 2009

Southern Screening Contract Now at $2 Mil. Year For Five Year

June 7, 1974